Literature DB >> 16078084

Bone mineral content in calcium renal stone formers.

A Trinchieri1.   

Abstract

Idiopathic renal calcium stone disease often presents with reduced bone mineral content. Investigations using non-invasive methods for the measurement of bone mineral content (single and dual-photon absorptiometry, dual-energy x-ray absorptiometry, quantitative computed tomodensitometry) show a slight decrease in skeletal mineral content of idiopathic renal stone formers (RSFs). The alterations in bone mineral content in RSFs have different explanations: prostaglandin-mediated bone resorption, subtle metabolic acidosis and 1-25 vitamin D disorders. Bone mineral content is worsened by insufficient dietary calcium leading to a negative calcium balance.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16078084     DOI： 10.1007/s00240-005-0498-y

Source DB:  PubMed          Journal:  Urol Res        ISSN： 0300-5623


  72 in total

1.  Calcium intake in patients with primary hyperparathyroidism.

Authors:  C E DENT; B V HARTLAND; J HICKS; E D SYKES
Journal:  Lancet       Date:  1961-08-12       Impact factor: 79.321

2.  Vertebral mineral content in diet-dependent and diet-independent hypercalciuria.

Authors:  L Borghi; T Meschi; A Guerra; L Maninetti; M Pedrazzoni; A Marcato; P Vescovi; A Novarini
Journal:  J Urol       Date:  1991-11       Impact factor: 7.450

3.  Involvement of low-calcium diet in the reduced bone mineral content of idiopathic renal stone formers.

Authors:  M Fuss; T Pepersack; J Van Geel; J Corvilain; J C Vandewalle; P Bergmann; J Simon
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

4.  Prevalence of renal stones in a population-based study with dietary calcium, oxalate, and medication exposures.

Authors:  M R Sowers; M Jannausch; C Wood; S K Pope; L L Lachance; B Peterson
Journal:  Am J Epidemiol       Date:  1998-05-15       Impact factor: 4.897

5.  "Idiopathic" hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect.

Authors:  M Tieder; D Modai; U Shaked; R Samuel; R Arie; A Halabe; J Maor; J Weissgarten; Z Averbukh; N Cohen
Journal:  N Engl J Med       Date:  1987-01-15       Impact factor: 91.245

6.  Primary hyperparathyroidism: clinical and biochemical features.

Authors:  L E Mallette; J P Bilezikian; D A Heath; G D Aurbach
Journal:  Medicine (Baltimore)       Date:  1974-03       Impact factor: 1.889

7.  Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria.

Authors:  A E Broadus; K L Insogna; R Lang; A F Ellison; B E Dreyer
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

8.  Hypouricemia, hypercalciuria, and decreased bone density: a hereditary syndrome.

Authors:  O Sperling; A Weinberger; I Oliver; U A Liberman; A De Vries
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

9.  Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria.

Authors:  A Ghazali; V Fuentès; C Desaint; P Bataille; A Westeel; M Brazier; L Prin; A Fournier
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

10.  Biochemical markers of bone turnover for the clinical assessment of bone metabolism.

Authors:  A K Taylor; S A Lueken; C Libanati; D J Baylink
Journal:  Rheum Dis Clin North Am       Date:  1994-08       Impact factor: 2.670
View more
  9 in total

1.  Bone mineral density status in urolithiasis patients with vitamin D inadequacy followed at a tertiary stone centre.

Authors:  Mohamed A Elkoushy; Mazen Jundi; Terence T N Lee; Sero Andonian
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

2.  Urinary stone risk factors in the descendants of patients with kidney stone disease.

Authors:  Thasinas Dissayabutra; Nuttiya Kalpongkul; Jakkhaphan Rattanaphan; Chanchai Boonla; Monpicha Srisa-Art; Wattanachai Ungjaroenwathana; Piyaratana Tosukhowong
Journal:  Pediatr Nephrol       Date:  2018-03-28       Impact factor: 3.714

3.  Relationship between renal stone formation, mitral annular calcification and bone resorption markers.

Authors:  Ahmet Celik; Vedat Davutoglu; Kemal Sarica; Sakip Erturhan; Orhan Ozer; Ibrahim Sari; Mustafa Yilmaz; Yasemin Baltaci; Murat Akcay; Behcet Al; Murat Yuce; Necat Yilmaz
Journal:  Ann Saudi Med       Date:  2010 Jul-Aug       Impact factor: 1.526

4.  Osteopenia/osteoporosis in patients with calcium nephrolithiasis.

Authors:  Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin; Maria Sierra Girón-Prieto; Antonio Poyatos-Andujar; Juan Garrido-Gomez; Armando Zuluaga-Gomez; Salvador Arias-Santiago
Journal:  Urol Res       Date:  2012-08-12

Review 5.  Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis.

Authors:  P Lucato; C Trevisan; B Stubbs; B M Zanforlini; M Solmi; C Luchini; G Girotti; S Pizzato; E Manzato; G Sergi; S Giannini; M Fusaro; N Veronese
Journal:  Osteoporos Int       Date:  2016-06-11       Impact factor: 4.507

6.  Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Prasad L Gawade; Kirsten K Ness; Shelly Sharma; Zhenghong Li; Deo Kumar Srivastava; Sheri L Spunt; Kerri Nottage; Matthew J Krasin; Melissa M Hudson; Sue C Kaste
Journal:  J Cancer Surviv       Date:  2012-09-06       Impact factor: 4.442

7.  Gender Representation of Osteoporosis in Patients with Urolithiasis.

Authors:  Radojka Bijelic; Milorad Balaban; Snjezana Milicevic
Journal:  Med Arch       Date:  2015-10-04

8.  Incidence of osteoporosis in patients with urolithiasis.

Authors:  Radojka Bijelic; Snjezana Milicevic; Jagoda Balaban
Journal:  Med Arch       Date:  2014-10-15

9.  Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.

Authors:  Asieh Mansour; Maryam Aboeerad; Mostafa Qorbani; Amir Pejman Hashemi Taheri; Mohamad Pajouhi; Abbas Ali Keshtkar; Bagher Larijani; Mohammad Reza Mohajeri-Tehrani; Mohammad Reza Ganji
Journal:  BMC Nephrol       Date:  2018-07-11       Impact factor: 2.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.